1040754-67-3
Chemical Structure
ST-539
- CAS No.: 1040754-67-3
- Formula:C30H31N3O4S
- Molecular Weight:529.65
IUPAC Name: N-(1-((5-(N-(tert-butyl)sulfamoyl)naphthalen-1-yl)amino)-1-oxo-3-phenylpropan-2-yl)benzamide
InChIKey: GIXYSOPAEGHVQN-UHFFFAOYSA-N
SMILES: O=C(NC1=C2C=CC=C(S(=O)(NC(C)(C)C)=O)C2=CC=C1)C(NC(C3=CC=CC=C3)=O)CC4=CC=CC=C4
Biological Activity: ST-539 is an orally active USP30 inhibitor that crosses the blood-brain barrier, with an IC50 of 0.37 μM. ST-539 blocks USP30-mediated removal of ubiquitin from Parkin substrates, induces Parkin-mediated mitophagy and apoptosis during mitochondrial stress, and inhibits the AKT/mTOR signaling pathway. ST-539 can be used for research on T-cell leukemia, Parkinson's disease, and colon adenocarcinoma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ST-539 | 99.00% | ST-539 is an orally active USP30 inhibitor that crosses the blood-brain barrier, with an IC50 of 0.37 μM. ST-539 blocks USP30-mediated removal of ubiquitin from Parkin substrates, induces Parkin-mediated mitophagy and apoptosis during mitochondrial stress, and inhibits the AKT/mTOR signaling pathway. ST-539 can be used for research on T-cell leukemia, Parkinson's disease, and colon adenocarcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhang R, et al. The Mitochondrial Deubiquitinase USP30 Regulates AKT/mTOR Signaling. Frontiers in pharmacology. 2022;13:816551.
- [2]. Yang P, et al. Mitophagy in Neurodegenerative Diseases: Mechanisms of Action and the Advances of Drug Discovery. Journal of medicinal chemistry. 2025 Feb 27;68(4):3970-3994. [Content Brief]
- [3]. Zhang R, et al. USP30 inhibition augments mitophagy to prevent T cell exhaustion. Science advances. 2025 Aug 15;11(33):eadv6902.
- [4]. Luo H, et al. Pharmacological inhibition of USP30 activates tissue-specific mitophagy. Acta physiologica (Oxford, England). 2021 Jul;232(3):e13666.
